Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

$ABCL
Pharmaceuticals and Biotechnology
Health Care
Get the next $ABCL alert in real time by email
SC 13G/A 1 tm226145d3_sc13ga.htm SC 13G/A

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 1) *

 

AbCellera Biologics Inc.

(Name of Issuer)

 

Common Shares, no par value per share

(Title of Class of Securities)

 

00288U106

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)

 

Page 1 of 17 Pages

Exhibit Index Contained on Page 16

 

 

 

 

 

 

CUSIP NO. 00288U106  13G  Page 2 of 17

 

1 NAME OF REPORTING PERSON          DCVC Bio, L.P. (“DCVC Bio”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
7,305,761 shares, except that DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, may be deemed to have sole voting power with respect to such shares, JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
6 SHARED VOTING POWER
See response to row 5.
7 SOLE DISPOSITIVE POWER
7,305,761 shares, except that DCVC Bio GP, the general partner of DCVC Bio, may be deemed to have sole dispositive power with respect to such shares, JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
8 SHARED DISPOSITIVE POWER
See response to row 7.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* PN

 

 

 

 

CUSIP NO. 00288U106  13G  Page 3 of 17

 

1 NAME OF REPORTING PERSON          DCVC Bio GP, LLC (“DCVC Bio GP”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”), for whom DCVC Bio GP serves as general partner, except that JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
6 SHARED VOTING POWER
See response to row 5.
7 SOLE DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio, for whom DCVC Bio GP serves as general partner, except that JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
8 SHARED DISPOSITIVE POWER
See response to row 7.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* OO

 

 

 

 

CUSIP NO. 00288U106  13G  Page 4 of 17

 

1 NAME OF REPORTING PERSON          JNK Capital Management, LLC (“JNK”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares.
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). JNK serves as a managing member of DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares.
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. JNK serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Stead and Hamer, the managing members of JNK, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* OO

 

 

 

 

CUSIP NO. 00288U106  13G  Page 5 of 17

 

1 NAME OF REPORTING PERSON          ZNM Capital Management, LLC (“ZNM”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares.
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). ZNM serves as a managing member of DCVC Bio GP (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares.
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. ZNM serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* OO

 

 

 

 

CUSIP NO. 00288U106  13G  Page 6 of 17

 

1 NAME OF REPORTING PERSON          Zachary Bogue (“Bogue”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Bogue, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Bogue, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* IN

 

 

 

 

CUSIP NO. 00288U106  13G  Page 7 of 17

 

1 NAME OF REPORTING PERSON          Matthew Ocko (“Ocko”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Ocko, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Ocko, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* IN

 

 

 

 

CUSIP NO. 00288U106  13G  Page 8 of 17

 

1 NAME OF REPORTING PERSON          Kiersten Stead (“Stead”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Stead, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Stead, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* IN

 

 

 

 

CUSIP NO. 00288U106  13G  Page 9 of 17

 

1 NAME OF REPORTING PERSON          John Hamer (“Hamer”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)          ¨         (b)          x          

3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON

 

WITH

 5 SOLE VOTING POWER
0 shares
6 SHARED VOTING POWER
7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Hamer, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Hamer, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
12 TYPE OF REPORTING PERSON* IN

 

 

 

 

CUSIP NO. 00288U106  13G  Page 10 of 17

 

ITEM 1(A).NAME OF ISSUER

 

AbCellera Biologics Inc.

 

ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

 

2215 Yukon Street

Vancouver, BC V5Y 0A1

 

ITEM 2(A).NAME OF PERSONS FILING

 

This Statement is filed by DCVC Bio, L.P., a Delaware limited partnership (“DCVC Bio”), DCVC Bio GP, LLC, a Delaware limited liability company (“DCVC Bio GP”), JNK Capital Management, LLC, a Delaware limited liability company (“JNK”), ZNM Capital Management, LLC, a Delaware limited liability company (“ZNM”), Zachary Bogue (“Bogue”), Matthew Ocko (“Ocko”), John Hamer (“Hamer”) and Kiersten Stead (“Stead”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

 

DCVC Bio GP is the general partner of DCVC Bio, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. ZNM is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. JNK is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Bogue and Ocko are managing members of ZNM and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Hamer and Stead are managing members of JNK and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio.

 

ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

 

The address for each of the Reporting Persons is:

 

270 University Avenue
Palo Alto, CA 94301

 

ITEM 2(C).CITIZENSHIP

 

DCVC Bio is a Delaware limited partnership. DCVC Bio GP, JNK and ZNM are Delaware limited liability companies. Bogue, Ocko, Hamer and Stead are United States citizens.

 

ITEM 2(D) AND (E).          TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER

 

Common Shares, no par value per share
CUSIP # 00288U106

 

ITEM 3.Not Applicable.

 

 

 

 

CUSIP NO. 00288U106  13G  Page 11 of 17

 

ITEM 4.OWNERSHIP

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)Amount beneficially owned:

 

See Row 9 of cover page for each Reporting Person.

 

(b)Percent of Class:

 

See Row 11 of cover page for each Reporting Person.

 

(c)Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote:

 

See Row 5 of cover page for each Reporting Person.

 

(ii)Shared power to vote or to direct the vote:

 

See Row 6 of cover page for each Reporting Person.

 

(iii)Sole power to dispose or to direct the disposition of:

 

See Row 7 of cover page for each Reporting Person.

 

(iv)Shared power to dispose or to direct the disposition of:

 

See Row 8 of cover page for each Reporting Person.

 

ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

 

ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

Under certain circumstances set forth in the limited partnership agreement of DCVC Bio, and the limited liability company agreements of DCVC Bio GP, JNK Capital Management, LLC and ZNM Capital Management, LLC, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as the case may be.

 

ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

 

Not applicable.

 

 

 

 

CUSIP NO. 00288U106  13G  Page 12 of 17

 

ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

 

Not applicable.

 

ITEM 9.NOTICE OF DISSOLUTION OF GROUP

 

Not applicable.

 

ITEM 10.CERTIFICATION

 

Not applicable.

 

 

 

 

CUSIP NO. 00288U106  13G  Page 13 of 17

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2021

 

    DCVC Bio, L.P.
     
    By:  DCVC Bio GP, LLC, its General Partner
     
    By: JNK Capital Management, LLC, its Managing Member
     
  By: /s/ John Hamer
  Name: John Hamer
  Title: Managing Member
     
  By: /s/ Kiersten Stead
  Name: Kiersten Stead
  Title: Managing Member
     
    By: ZNM Capital Management, LLC, its Managing Member
     
  By: /s/ Matthew Ocko
  Name: Matthew Ocko
  Title: Managing Member
     
  By: /s/ Zachary Bogue
  Name: Zachary Bogue
  Title: Managing Member
     
    DCVC Bio GP, LLC
     
    By: JNK Capital Management, LLC, its Managing Member
     
  By: /s/ John Hamer
  Name: John Hamer
  Title: Managing Member
     
  By: /s/ Kiersten Stead
  Name: Kiersten Stead
  Title: Managing Member
     
    By: ZNM Capital Management, LLC, its Managing Member
     
  By: /s/ Matthew Ocko
  Name: Matthew Ocko
  Title: Managing Member

 

 

 

 

CUSIP NO. 00288U106  13G  Page 14 of 17

 

  By: /s/ Zachary Bogue
  Name: Zachary Bogue
  Title: Managing Member
     
    JNK Capital Management, LLC
     
  By: /s/ John Hamer
  Name: John Hamer
  Title: Managing Member
     
  By: /s/ Kiersten Stead
  Name: Kiersten Stead
  Title: Managing Member
     
    ZNM Capital Management, LLC
     
  By: /s/ Matthew Ocko
  Name: Matthew Ocko
  Title: Managing Member
     
  By: /s/ Zachary Bogue
  Name: Zachary Bogue
  Title: Managing Member
     
    John Hamer
     
  By: /s/ John Hamer
  Name: John Hamer
     
    Kiersten Stead
     
  By: /s/ Kiersten Stead
  Name: Kiersten Stead
     
    Matthew Ocko
     
  By: /s/ Matthew Ocko
  Name: Matthew Ocko
     
    Zachary Bogue
     
  By: /s/ Zachary Bogue
  Name: Zachary Bogue

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

 

 

 

CUSIP NO. 00288U106  13G  Page 15 of 17

 

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

 

 

 

 

CUSIP NO. 00288U106  13G  Page 16 of 17

 

EXHIBIT INDEX

 

  Found on
Sequentially
Exhibit Numbered Page
   
Exhibit A:  Agreement of Joint Filing 17

 

 

 

 

CUSIP NO. 00288U106  13G  Page 17 of 17

 

exhibit A

 

Agreement of Joint Filing

 

The Reporting Persons hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares of AbCellera Biologics Inc. shall be filed on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

 

 

 
Get the next $ABCL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABCL

DatePrice TargetRatingAnalyst
8/20/2024Buy → Hold
The Benchmark Company
2/22/2024$9.00Hold → Buy
The Benchmark Company
12/5/2023$6.00Overweight
KeyBanc Capital Markets
11/6/2023Buy → Hold
The Benchmark Company
10/13/2023$20.00Overweight
Piper Sandler
2/28/2023Outperform
Cowen
12/15/2022$30.00Buy
Goldman
11/16/2022$29.00Buy
Truist
More analyst ratings

$ABCL
 Press Releases

Fastest customizable press release news feed in the world

See more

  • AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

    AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

    AbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois. Details on AbCellera's poster presentation at AACR are as follows: Title: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer Abstract Number: 6012 Session: Therapeutic Antibodies, Including Engineered Antibodies 2 Date and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT Location: Section 35, Board 7 About AbCellera's T-Cell Engager Pl

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • AbCellera Reports Full Year 2024 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

$ABCL
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ABCL
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ABCL
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ABCL
 SEC Filings

See more

$ABCL
 Leadership Updates

Live Leadership Updates

See more

  • AbCellera Announces Resignation of Board Member

    AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

    TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • AbCellera Announces Changes to Its Board of Directors

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

$ABCL
 Financials

Live finance-specific insights

See more

  • AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

    AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • AbCellera Reports Full Year 2024 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

  • AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

    AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, da

    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care

$ABCL
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more